SCHEMBL19965818

SCHEMBL19965818

CCOC(=O)N1CCC(N2CCC3(CC2)OC(=O)NC3(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 3/20 0.48
TP53 P04637 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CHRM2 P08172 2/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM3 P20309 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 2/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KCNH2 Q12809 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18075926 0.86 CHRM4 (0.40) CHRM1TP53TDP1CHRM2CHRM4
SCHEMBL18075912 0.85 CHRM4 (0.43) CHRM1TP53TDP1CHRM2CHRM4
SCHEMBL17101418 0.84 CHRM1 (0.41) CHRM1CHRM2CHRM4CHRM5KCNH2
SCHEMBL18075932 0.84 CHRM4 (0.47) CHRM1TP53TDP1CHRM2CHRM4
SCHEMBL19965839 0.79 TP53 (0.47) CHRM1TP53TDP1CHRM2CHRM4
SCHEMBL19965819 0.79 CHRM1 (0.47) CHRM1TP53TDP1CHRM2CHRM4
SCHEMBL8525320 0.75 CHRM1 (0.51) CHRM1TP53TDP1CHRM2CHRM4
SCHEMBL20942004 0.74 CXCR3 (0.34) CHRM1CHRM4CHRM5SMN1; SMN2GAA
SCHEMBL19965929 0.73 CHRM1 (0.51) CHRM1TP53TDP1CHRM2CHRM4
SCHEMBL18075944 0.73 CHRM4 (0.38) CHRM2CHRM4MAPK1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
US-10167284-B2 Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor HEPTARES THERAPEUTICS LIMITED (GB) 2019-01-01 US disclosed
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR NXERA PHARMA UK LIMITED (GB) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10167284-B2 Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor CHRM1, CHRM2, CHRM4 CHRM1 1/4885TP53 2027/4885TDP1 4028/4885
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR CHRM1, CHRM2, CHRM4 CHRM1 1/4885TP53 2190/4885TDP1 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.